Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients
2021-000673-83Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Started Feb 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000673-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000673-83.